c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells

Chronic lymphocytic leukemia (CLL) is a malignancy characterized by clonal expan-sion of mature B cells that are resistant to apoptosis. This resistance to apoptosis partly results from Mcl-1 expression be-cause high levels of this protein in CLL cells correlate with poor disease prognosis and resistance to chemotherapy. Thus, under-standing the mechanism(s) regulating Mcl-1 expression in CLL cells may be useful in the development of new therapies for this incurable disease. In the present study, we show a strong relationship between c-Abl and Mcl-1 expression in CLL cells. We show that treatment of CLL cells with Abl-specific siRNA or with imatinib, to inhibit c-Abl activity, results in the down-regulation of Mcl-1 protein and mRNA. A major regulator of Mcl-1 gene expression is STAT3. Our data show that CLL cells expressing high levels of c-Abl also show elevated levels of phospho-STAT3, and that STAT3 phosphorylation in CLL cells is dependent on c-Abl activity. However, STAT3 phosphorylation by c-Abl requires activation of nuclear factor-B, secretion of autocrine interleukin-6, and active pro-tein kinase C. Taken together, our data demonstrate the mechanism involved in c-Abl regulation of Mcl-1 expression in CLL cells, and suggest that c-Abl inhibi-tion has therapeutic application in the treatment of this disease. (Blood. 2011; 117(8):2414-2422